Vaccine adverse events reported in New Zealand 1990-5

New Zealand Medical Journal

Volumn 110, Issue 1048, 1997, Pages 270-272

  Mansoor, Osman ^a   Pillans, Peter I ^b  

^a MINISTRY OF HEALTH   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; VACCINE;

ADVERSE DRUG REACTION; ARTICLE; CRYING; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; IMMUNIZATION; INJECTION SITE; NEUROTOXICITY; NEW ZEALAND; RASH; SIDE EFFECT; SKIN MANIFESTATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; INFANT; NEW ZEALAND; VACCINES;

EID: 0030812267     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Duclos P, Bentsi-Enchill A. Current thoughts on the risks and benefits of immunisation. Drug Safety 1993; 8: 404-13.
2. Stehr-Green P, Baker M, Belton A, et al. Immunisation Coverage in New Zealand. Communicable Dis NZ 1992; 92 (Suppl 2).
3. McNicholas A, Baker M. Immunisation coverage in New Zealand: ongoing surveillance using benefit claim data. NZ Public Health Rep 1995; 2: 1-3.
4. Rubella immunisation (editorial). NZ Med J 1982; 95: 321.
5. Ministry of Health. Immunisation Handbook, 2nd ed. Wellington: Ministry of Health, 1996.
6. Cody CL, Baraff LJ, Cherry JD, et al. Nature and rates of adverse reactions associated with DTP and DT immunisations in infants and children. Pediatrics 1981; 68: 650-60.
7. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. Lancet 1986; 1: 939-42.
8. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331:1397-402.
9. Department of Health. Measles rubella immunisation campaign in England. 'One year on'. London: Department of Health, 1995.
10. Black SB, Shinefield HR, Lampert D, et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOc) vaccine in infancy. Pediatr Infect Dis J 1991; 10: 92-6.
11. Decker MD, Edwards KM, Bradley R, Palmer R. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992; 120: 184-9.
12. Anonymous. Preventing local reactions with toxoid vaccines. Prescriber Update 1993; 1: 12-3.
13. Stratton KR, Howe CJ, Johnston RB. Adverse events associated with childhood vaccines other than pertussis and rubella. JAMA 1994; 271: 1602-5.
14. Macko MB, Powell CE. Comparison of the morbidity of tetanus toxoid with tetanus-diphtheria toxoid boosters. Ann Emerg Med 1985; 14: 33-5.
15. Deacon SP, Langford DT, Shepherd WM, Knight PA. A comparative study of adsorbed tetanus vaccine and adult-type tetanus-diphtheria vaccine. J Hyg Camb 1982: 89: 513-9.
16. Circular letter to health professionals. Wellington: Public Health Commission. June 1995.
17. Chen RT, Haber P, Mullen JR. Surveillance of the safety of simultaneous administration of vaccines. Ann NY Acad Sci 1995; 31: 309-20.
18. Roberts JD, Roos LL, Poffenroth LA, et al. Surveillance of vaccine-related adverse events in the first year of life: a Manitoba cohort study. J Clin Epidemiol 1996; 49: 51-8.
19. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345: 567-9.